Formulary and Prescribing Guidelines
|
|
- Emma Todd
- 6 years ago
- Views:
Transcription
1 Frmulary and Prescribing Guidelines SECTION 8: MANAGEMENT OF ACUTELY DISTURBED BEHAVIOUR
2 8. Rapid Tranquillisatin 8.1 Management f acutely disturbed ADULTS Befre cnsidering pharmaclgical measures: (see CLG52 fr mre infrmatin) Cnsider de-escalatin, using nn drug appraches: seclusin/mving t a lw stimulus area, talking dwn, time ut, distractin If pssible, d a mental state examinatin and physical state examinatin, take a histry including drug/alchl status, drug sensitivities, cncurrent medicatin Check fr intercurrent illness and recent illicit substance use Establish a wrking diagnsis Check fr any advance directive in relatin t medicines NON-PHARMACOLOGICAL MEASURES UNSUCCESSFUL INAPPROPRIATE L E V E L 1 Disturbed BUT accepting ral medicatin L E V E L 2 Disturbed AND refusing ral medicatin nurse in a quiet area Review all medicatin prescribed within last nging verbal de-escalatin 24hurs (BNF limits, side effects etc) fd and fluid t be prvided Cnsultant pinin may have t be sught review current medicatin decide whether additinal medicatin required PARENTERAL interventins (IM) AL interventins (PO) Lrazepam (1-2mg; max 4mg/24H) Can be repeated after 1 hur Dse shuld be reduced by 50% in patients taking sdium valprate Halperidl (5-10mg; max 20mg/24H) Can be repeated after 1 hur Ensure cardiac status f patient is knwn, preferably with previus ECG Chlrprmazine mg (Max 300mg/24H Can be repeated after 1 Hur Risperidne (2mg) Ordispersible tablets may be cnsidered if the patient is likely t spit ut the tablets Can be repeated after 2 hurs Olanzapine (10mg) Ordispersible tablets may be cnsidered if the patient is likely t spit ut the tablet Can be repeated after 2 hurs Lrazepam IM (1-2mg; max 4mg/24H) Sedatin in mins; peaks 1-3 hurs; Lasts 4-6 hurs, dse shuld be reduced by 50% in patients taking sdium valprate Prmethazine IM (50mg; 100 mg/24h) Can be repeated in 1-2 hurs, may be used in benzdiazepine-tlerant patients Prmethazine is the first line alternative during shrtages f lrazepam AND/ Halperidl IM (5mg; max 12mg/24H) Use alne r in cmbinatin with lrazepam, sedatin in 10 mins, peaks in mins, half life hurs, Ensure cardiac status f patient is knwn, preferably with previus ECG Olanzapine IM as mntherapy (5-10mg; max 20mg/24H) Peaks in mins D nt repeat within 2 hurs D nt use lrazepam within ne hur f administering lanzapine IM Cnsultant s direct invlvement mandatry Cnsult n-call pharmacist Secnd pinin f anther cnsultant Avid Diazepam if ECT is being cnsidered L E V E L 3 Prmethazine 50mg IM Diazepam 10mg IV ver at least 5 minutes. Can be repeated up t 3 times if insufficient effect. 2 Apprved by Medicines Management Grup Octber 2016
3 8. Rapid Tranquillisatin 8.2 Management f acutely disturbed OLDER ADULTS Befre cnsidering pharmaclgical measures: (see CLG52 fr mre infrmatin) Cnsider de-escalatin, using nn drug appraches: seclusin/mving t a lw stimulus area, talking dwn, time ut, distractin If pssible, d a mental state examinatin and physical state examinatin, taking int accunt frailty, drug/alchl status, drug sensitivities, cncurrent medicatin, dementia Check fr intercurrent illness and recent illicit substance use Establish a wrking diagnsis Check fr any advance directive in relatin t medicines NON-PHARMACOLOGICAL MEASURES UNSUCCESSFUL INAPPROPRIATE L E V E L 1 Disturbed BUT accepting ral medicatin L E V E L 2 Disturbed AND refusing ral medicatin nurse in a quiet area Review all medicatin prescribed within last nging verbal de-escalatin 24hurs (BNF limits, side effects etc) fd and fluid t be prvided Cnsultant pinin may have t be sught review current medicatin decide whether additinal medicatin required PARENTERAL interventins (IM) AL interventins (PO) Lrazepam (0.5-1mg; max 2mg/24H) Can be repeated after 1 hur Dse shuld be reduced by 50% in patients taking sdium valprate. Wrsens cnfusin in BPSD Halperidl (1-3mg; max 10mg/24H) Can be repeated after 1 hur Ensure cardiac status f patient is knwn, preferably with previus ECG Risperidne (0.5-1mg) Ordispersible tablets may be cnsidered if the patient is likely t spit ut the tablets Can be repeated after 2 hurs Preferred ptin in BPSD Olanzapine (2.5-5mg) Ordispersible tablets may be cnsidered if the patient is likely t spit ut the tablet Can be repeated after 2 hurs Lrazepam IM (0.5-1mg; max 2mg/24H) Sedatin in mins; peaks 1-3 hurs; Lasts 4-6 hurs, dse shuld be reduced by 50% in patients taking sdium valprate D nt use lrazepam within ne hur f administering lanzapine IM Prmethazine IM (25mg; 50mg/24H) Can be repeated in 1-2 hurs, may be used in benzdiazepine-tlerant patients Prmethazine is the first line alternative during shrtages f lrazepam AND/ Halperidl IM (1-2mg; max 10mg/24H) Use alne r in cmbinatin with lrazepam, sedatin in 10 mins, peaks in mins, half life hurs, Ensure cardiac status f patient is knwn (ECG) Olanzapine IM as mntherapy (5-10mg; max 20mg/24H) Peaks in mins D nt repeat within 2 hurs L E V E L 3 Refer t cnsultant Refer t cnsultant 3 Apprved by Medicines Management Grup Octber 2016
4 8. Rapid Tranquillisatin 8.3 Management f acutely disturbed CHILDREN & ADOLESCENTS Befre cnsidering pharmaclgical measures: (see CLG52 fr mre infrmatin) Cnsider de-escalatin, using nn drug appraches: seclusin/mving t a lw stimulus area, talking dwn, time ut, distractin If pssible, d a mental state examinatin and physical state examinatin, take a histry including drug/alchl status, drug sensitivities, cncurrent medicatin Check fr intercurrent illness and recent illicit substance use Establish a wrking diagnsis Check fr any advance directive in relatin t medicines NON-PHARMACOLOGICAL MEASURES UNSUCCESSFUL INAPPROPRIATE L E V E L 1 Disturbed BUT accepting ral medicatin nurse in a quiet area nging verbal de-escalatin fd and fluid t be prvided review current medicatin decide whether additinal medicatin required If patient is unknwn t services initially treat with Lrazepam and avid antipsychtics if pssible AL interventins (PO) Lrazepam ( 12 yrs 1-2mg, max 4mg/24H; <12 yrs 0.5-1mg, max 2mg/24H) Can be repeated after 1 hur Reduce dse by 50% in patients taking sdium valprate Prmethazine ( 12 yrs 25-50mg; <12 yrs 10-25mg) Can be repeated after 1 hur Halperidl ( 12 yrs 1-5mg, max 10mg/24H; <12 yrs 0.5-3mg, max 5mg/24H) Can be repeated after 1 hur Ensure cardiac status f patient is knwn, preferably with previus ECG Risperidne ( 12 yrs 1-2mg; <12 yrs 0.5-1mg) Ordispersible tablets may be cnsidered if the patient is likely t spit ut the tablets Can be repeated after 2 hurs Olanzapine ( 12 yrs 10mg) Ordispersible tablets may be cnsidered if the patient is likely t spit ut the tablet Can be repeated after 2 hurs L E V E L 2 Disturbed AND refusing ral medicatin Review all medicatin prescribed within last 24hurs (BNF limits, side effects etc) Cnsultant pinin may have t be sught PARENTERAL interventins (IM) Lrazepam IM ( 12 yrs 1-2mg, max 4mg/24H; <12 yrs 0.5-1mg, max 2mg/24H) Sedatin in mins; peaks 1-3 hurs; lasts 4-6 hurs Dse shuld be reduced by 50% in patients taking sdium valprate Prmethazine IM ( 12 yrs 25-50mg; <12 yrs 10-25mg) Prmethazine is the first line alternative during shrtages f lrazepam Halperidl IM ( 12 yrs 1-5mg, max 10mg/24H; <12 yrs 0.5-3mg, max 5mg/24H) Sedatin in 10 mins; peaks in mins; halflife hurs Use alne r in cmbinatin with Lrazepam Ensure cardiac status f patient is knwn, preferably with previus ECG Olanzapine IM as mntherapy ( 12 yrs 5-10mg, max 3 injectins/24h) Peaks in mins D nt repeat within 2 hurs D nt use lrazepam within ne hur f administering lanzapine IM Quetiapine ( 12 yrs 25-50mg; <12 yrs mg) Can be repeated after 2 hurs 4 Apprved by Medicines Management Grup Octber 2016
5 8. Rapid Tranquillisatin 8.4 Drugs apprved fr management f acute disturbed behaviur See latest BNF fr licensed indicatins. Drug and frm Time t max. plasma Cnc. Half life Halperidl IM injectin mins hurs Halperidl slutin 3-6 hurs hurs Halperidl tab 3-6 hurs hurs Cmments Lrazepam IM injectin mins hurs The FDA has warned f a serius risk f death when benzdiazepines are Lrazepam tabs 2 hurs 12 hurs used in cmbinatin with Opiid analgesic r cugh preparatins. 6 Olanzapine dispersible tab. 5-8 hurs hurs Olanzapine injectin mins hurs Olanzapine tab 5-8 hurs hurs Prmethazine IM injectin 2-3 hurs 5-14 hurs Risperidne dispersible tab. 1-2 hurs 24 hurs Risperidne liquid 1-2 hurs 24 hurs Risperidne tab 1-2 hurs 24 hurs IM lanzapine may prduce a 5-fld increase in plasma cnc. vs. the same dse given rally 8.5 Guidelines fr the use f Flumazenil Indicatins fr use Cntra-indicatins Cautins Dse & rute f administratin (in adults) Time befre the dse can be repeated Maximum dse: Side effects Respiratry rate < 10/minute after administratin f benzdiazepines Patients with epilepsy wh have been receiving lng-term benzdiazepines Dse shuld be carefully titrated in hepatic impairment Initially: 200 mcg intravenusly ver 15 secnds 60 secnds Subsequent dse: 100 mcg ver 10 secnds as required (up t 8 dses) 1 mg in 24 hurs (ne initial dse and eight subsequent dses) Patients may becme agitated, anxius, r fearful n awakening. Seizures may ccur in regular benzdiazepine users Respiratry rate shuld be mnitred cntinuusly until respiratry rate returns t baseline level. Flumazenil has a shrt half-life (much shrter than diazepam) and respiratry functin may recver then deterirate again. Nte: If respiratry rate des nt return t nrmal r patient is nt alert after initial dses give, then assume sedatin is due t sme ther cause. 5 Apprved by Medicines Management Grup Octber 2016
6 8. Rapid Tranquillisatin 8.6 Acute Disturbed Behaviur Mnitring Errr! Reference surce nt fund. After any parenteral drug administratin, mnitr and recrd n the MEWS chart the fllwing: 1. Temperature 2. Pulse 3. Bld pressure 4. Respiratin rate Every 5-10 minutes fr ne hur and then half hurly until patient is ambulatry. If the patient is asleep r uncnscius, the cntinuus use f pulse ximetry t measure xygen saturatin is desirable. A nurse shuld remain with the patient until ambulatry. ECG and haematlgical mnitring are als necessary when parenteral antipsychtics are administered, especially when higher dses are used. Hypkalaemia, stress and agitatin place the patient at risk f cardiac arrhythmias. A crash bag shuld be available within 3 minutes 8.7 Remedial Measures in ADULTS 1 Prblem Acute Dystnia (including culgyric crisis) Reduced respiratry rate (<10 per minute) Or xygen saturatin (<90%) Irregular r slw pulse (<50/min) Fall in Bld pressure (>30 mmhg rthstatic drp r <50 mmhg diastlic) Increased Temperature Remedial Measures Give prcyclidine 5-10mg IM Give xygen raise legs; Ensure that patient is nt lying face dwn. Give flumazenil if benzdiazepine-induced respiratry depressin suspected. If induced by any ther sedative agent and Dr is nt immediately available: TRANSFER TO A MEDICAL BED AND VENTILATE MECHANICALLY Refer t specialist medical care immediately Lie patient flat, tilt bed twards head. Mnitr clsely. Withhld antipsychtics: (risk f NMS and perhaps arrhythmias). Check Creatinine kinase 8.8 Guidelines fr the Use f Clpixl Acuphase (zuclpenthixl acetate) Acuphase shuld nly be used after an acutely psychtic patient has required repeated injectins f shrt-acting antipsychtic drugs such as halperidl r lanzapine r sedative drugs such as lrazepam. Acuphase shuld nly be given when enugh time has elapsed t assess the full respnse t previusly injected drugs therefre allw 15 minutes after IV injectins r 60 minutes after IM administratin. Acuphase shuld never be administered: In an attempt t hasten the antipsychtic effect f any ther antipsychtic therapy Fr rapid tranquillisatin At the same time as ther parenteral antipsychtics r benzdiazepines At the same time as dept medicatin 6 Apprved by Medicines Management Grup Octber 2016
7 8. Rapid Tranquillisatin As a test dse fr zuclpenthixl decanate dept T a patient wh is physically resistive (risk f intravasatin and il emblus). T patients wh accept ral medicatin T patients wh are antipsychtic-naïve T patients wh are less than 12 years ld. T patients wh are sensitive t EPSE T patients wh are uncnscius T patients wh are pregnant T patients with hepatic r renal impairment T patients with cardiac disease Dse Onset and duratin f actin Acuphase shuld be given in a dse f mg, up t a maximum f 400mg ver a tw week perid. This maximum duratin ensures that a treatment plan is put in place. It des nt indicate that there are knwn harmful effects frm mre prlnged administratin, althugh such use shuld be very exceptinal. There is n such thing as a curse f Acuphase. The patient shuld be assessed befre each administratin. Injectins shuld be spaced at least 24 hurs apart. Nte, Zuclpenthixl acetate is widely misused as a srt f chemical straightjacket. In reality, it is a ptentially txic preparatin with very little published infrmatin t supprt its use. It is perhaps best reserved fr thse few patients wh have a prir histry f gd respnse t Acuphase that is, thse patients wh have an advance directive recmmending the use f Acuphase during psychtic episdes. Sedative effects usually begin t be seen 2 hurs after injectin and peak after 12 hurs. The effects may last fr up t 72 hurs. Nte: Acuphase has n place in rapid tranquillisatin: its actin is nt rapid. 8.9 NICE Clinical Guidelines NICE NG10, May 2015, Vilence and Aggressin: Shrt term management in mental health, health and cmmunity settings. NICE defines Rapid Tranquillisatin as the use f medicatin by the parenteral rute (usually intramuscular r exceptinally, intravenus) if ral medicatin is nt pssible r apprpriate and urgent sedatin with medicatin is needed. All staff that prescribe and administer the abve medicatins shuld be: Aware f the risks assciated with pharmaclgical management f acutely disturbed patients, such as: damage t the therapeutic relatinship between service user and Health Care Prfessinal (NICE endrses requesting service users accunts f their experiences upn discharge t anther unit) 7 Apprved by Medicines Management Grup Octber 2016
8 8. Rapid Tranquillisatin ver-sedatin leading t lss f alertness and lss f cnsciusness (NICE guidelines mandate that the service user must be able t respnd t cmmunicatin thrughut and if verbal cmmunicatin is lst, then the same level f care as fr general anaesthesia must be used). cardivascular and respiratry cllapse [see mnitring after administratin which cnsists f: temperature (risk f neurleptic malignant syndrme), respiratin rate, xygen saturatin, BP, HR (pulse), level f cnsciusness and any evidence f EPSE. The physical and mental status f the service user shuld be taken int accunt in deciding the initial dse and subsequent dse increments. interactin f the medicines used in management with medicines already taken by the patient (whether prescribed by his/her GP, r illicit) Familiar with the medicines used in management, their crrect prescriptin, and that ral (PO) and intramuscular (IM) dses must be prescribed separately that tw drugs f the same class shuld nt be written tgether (fr example, d nt write up diazepam and lrazepam, and/r halperidl * and lanzapine n the prn side f the drug chart) that medicatins shuld nt be mixed in the same syringe (that is, lrazepam shuld be given by separate injectin and site, frm a cncurrent halperidl injectin if cmbined antipsychtic/ benzdiazepine is clinically required) the NEED F CONSENT, r else ensure that the apprpriate Mental Health Sectin(s) is in place the prperties f drugs used that is BNF and SPC requirements, including need fr baseline ECG and the ptential f individual drugs t lengthen (directly r indirectly) the QTc interval. Additinally they must knw the ttal daily dses allwed and the need t titrate dse t effect. the risks assciated with particular classes f medicines: Benzdiazepines: lss f cnsciusness; respiratry depressin r arrest; cardivascular cllapse when receiving bth clzapine and benzdiazepines Antipsychtics: excessive sedatin; lss f cnsciusness; cardivascular/respiratry cmplicatins and cllapse; seizures; akathisia; dystnia; dyskinesia; neurleptic malignant syndrme Antihistamines: excessive sedatin; painful injectin; additinal antimuscarinic effects the medicines NOT recmmended, namely: 8 Apprved by Medicines Management Grup Octber 2016
9 8. Rapid Tranquillisatin PO/IM chlrprmazine IM diazepam Thiridazine (n lnger marketed in the UK) IM dept antipsychtics Olanzapine (fr dementia-related disturbance) Zuclpenthixl acetate due t lng nset and duratin f actin. Hwever, it may be cnsidered as an ptin where there is a past histry f gd and timely respnse, r where there is an advance directive and when the service user has a histry f disturbed behaviur ver an extended time perid. Aware that there are preferred levels f administratin (the preferred methd f drug administratin being PO, then intramuscular IM and then, and nly if immediate tranquillisatin is essential, IV) and that: if patient will accept ral and is nt psychtic, NICE recmmends ral lrazepam. Alternatively, if psychtic and taking ral, cnsider an antipsychtic (e.g. halperidl r lanzapine) in additin t ral lrazepam. if patient will nt accept ral (r, frm previus experience, this is cnsidered ineffective) cnsider IM lrazepam fr nn-psychtic patients. Alternatively, if psychtic and nt accepting ral, cnsider use f IM lrazepam in additin t IM antipsychtic (e.g. halperidl r lanzapine). IM Lrazepam and IM Olanzapine can nly be given cncurrently if a minimum f ne hur has elapsed between the tw agents (When using antipsychtics parenterally, ensure ready availability f parenteral prcyclidine. NICE als recmmends parenteral benztrpine, but this prduct has, since, been discntinued in the UK.) Familiar with pst management prcedures, such as: Regular mnitring and recrding f BP, HR (pulse), RR, O2 saturatins, level f cnsciusness, EPSE and temperature; the frequency f which must be increased if IM/IV administratin has been used BNF/SPC dsages have been exceeded High-risk situatins such as knwn/suspected illicit drug use Patient has a significant medical histry/is n prescribed medicatin If verbal respnsiveness is lst use same level f mnitring as fr general anaesthesia Upn transfer t anther unit, ensure that full dcumentatin is cmplete with: Full medicatin histry (that is, which medicines were/were nt effective and any adverse drug interactins); Frmulatin f advance directive(s); Service user s accunt f their experience (if feasible). Apprved by Medicines Management Grup Octber
10 8. Rapid Tranquillisatin References 1. The Suth Lndn and Maudsley NHS Fundatin Trust and Oxleas NHS Fundatin Trust 2015 Prescribing Guidelines. 12 th Editin. Wiley Blackwell 2. NICE CG 25, Feb 2005 Vilence: The shrt-term management f disturbed/vilent behaviur in psychiatric in-patient settings and emergency departments (Accessed Dec 2015) 3. British Natinal Frmulary (70 th Editin, September 2015) 4. Summary f Prduct Characteristics[accessed Dec 2015] 5. NICE NG 10 May Vilence and Aggressin: Shrt term management in mental health, health and cmmunity settings Accessed September 2016 Apprved by Medicines Management Grup Octber
SECTION 8: MANAGEMENT OF ACUTELY DISTURBED BEHAVIOUR. Formulary and Prescribing Guidelines
SECTION 8: MANAGEMENT OF ACUTELY DISTURBED BEHAVIOUR Frmulary and Prescribing Guidelines 8.1 Management f acutely disturbed ADULTS : (See CG52 fr full guidelines) Befre cnsidering pharmaclgical measures:
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationPain relief after surgery
Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationAppendix C Guidelines for treating status epilepticus in adults and children
Appendix C Guidelines fr treating status epilepticus in adults and children 1.1 Treating cnvulsive status epilepticus in adults General measures 1st stage (0 10 minutes) Secure airway and resuscitate Administer
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationIschemic heart disease (angina/chest pain)
Ischemic heart disease (angina/chest pain) External resurces Stable angina: management NICE guidelines [CG126] Updated :Aug 2016 https://www.nice.rg.uk/guidance/cg126 Chest pain f recent nset [CG95] Nvember
More informationFormulary and Prescribing Guidelines
SECTION 7: MANAGEMENT OF DEMENTIA Frmulary and Prescribing Guidelines 7.1 Apprved drugs fr use in cgnitive impairment f Alzheimer s disease Drug 3 Frmulatin 3 Dse 3 Licensed 4 Dnepezil Tablets 5 mg, 10
More informationGuidelines for the Admission of Children and Young People with an Eating Disorder
Guidelines fr the Admissin f Children and Yung Peple with an Eating Disrder This dcument is designed t be used by clinicians lcated in hspitals f wards withut specialist eating disrder facilities, t guide
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationMedication Guide MORPHINE SULFATE (mor-pheen) Oral Solution (CII)
Medicatin Guide MORPHINE SULFATE (mr-pheen) Oral Slutin (CII) IMPORTANT: Keep Mrphine Sulfate Oral Slutin in a safe place away frm children. Accidental use by a child is a medical emergency and can cause
More informationAppendix 1 Example of Homely Remedy Policy
Appendix 1 Example f Hmely Remedy Plicy Hmely Remedy Plicy - EXAMPLE This plicy applies t (insert name f Care Hme) Definitin A hmely (r husehld) remedy is a medicinal prduct fr the shrt-term treatment
More informationPackage leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate
Package leaflet: Infrmatin fr the user Daceptn 5 mg/ml Slutin fr infusin Apmrphine hydrchlride hemihydrate Read all f this leaflet carefully befre yu start using this medicine because it cntains imprtant
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. RHEUMATOLOGY SHARED CARE GUIDELINE for DMARDs
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE RHEUMATOLOGY SHARED CARE GUIDELINE fr DMARDs There are currently 6 Disease-mdifying anti rheumatic drugs (DMARDs) in rutine use by the Lutn & Dunstable
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationMEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP
MEDICATION GUIDE Piglitazne and Metfrmin Hydrchlride (PYE GLI ta zne and met FOR min HYE-dre- KLOR-ide)Tablets, USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride
More informationHerbal Medicines: Traditional Herbal Registration
Herbal Medicines: Traditinal Herbal Registratin In the UK, cmpanies can nly sell herbal medicines with the apprpriate prduct licence, as fllws: A full marketing authrisatin based n the safety, quality
More informationOpioid Analgesics PA Request Provider Checklist
WVP Health Authrity Updated 05-12-2015 Opiid Analgesics PA Request Prvider Checklist *** If pssible, please include the fllwing infrmatin with PA requests fr piid analgesics. Including the requested infrmatin
More informationMEDICATION GUIDE. (fingolimod) capsules
MEDICATION GUIDE GILENYA (je-len-yah) (finglimd) capsules Read this Medicatin Guide befre yu start using GILENYA and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take the
More informationYou may have a higher risk of bleeding if you take warfarin sodium tablets and:
MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationDRAFT Policy for the Management of Ear Wax
Clinical Cmmissining Grup (CCG) Treatment Plicy NHS Birmingham and Slihull Clinical Cmmissining Grup NHS Sandwell and West Birmingham Clinical Cmmissining Grup DRAFT Plicy fr the Management f Ear Wax 1
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationPsychological aspects of breast cancer. Dr Caroline Dancyger & Dr Esther Hansen
Psychlgical aspects f breast cancer Dr Carline Dancyger & Dr Esther Hansen Cmmn acrss all cancers Adjustment as the nrm Diagnsis End f active treatment r Discharge Palliative Care Recurrence distress t
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationGeneric Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations
Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationUse of sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Shared Care Protocol
Oxfrdshire Clinical Cmmissining Grup Use f sacubitril valsartan fr the treatment f symptmatic chrnic heart failure with reduced ejectin fractin. Shared Care Prtcl This prtcl prvides prescribing and mnitring
More informationFormulary and Prescribing Guidelines
Frmulary and Prescribing Guidelines SECTION 1: TREATMENT OF DEPRESSION 1.1 Intrductin This guidance shuld be cnsidered as part f a stepped care apprach in the management f depressive disrders. Antidepressants
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationCONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS
CONSENT FORM - TESTOSTERONE FOR TRANSGENDER CLIENTS Yu want t take teststerne t masculinize yur bdy. Befre taking it, there are several things yu need t knw abut. They are the pssible advantages, disadvantages,
More informationSECTION 2: TREATMENT OF PSYCHOSIS. Formulary and Prescribing Guidelines
SECTION 2: TREATMENT OF PSYCHOSIS Frmulary and Prescribing Guidelines 2.1 Principles f Antipsychtic Prescribing Where pssible, chice f antipsychtic shuld be made jintly by the patient and the clinician
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationMedication Guide ABSTRAL (AB-stral) CII (fentanyl) Sublingual tablets
Medicatin Guide ABSTRAL (AB-stral) CII (fentanyl) Sublingual tablets IMPORTANT: D nt use ABSTRAL unless yu are regularly using anther piid pain medicine arund-the-clck fr at least ne week r lnger fr yur
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationMy Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)
My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made
More information3. After I.V. or S.C. administration, onset is rapid, usually within 30 seconds, with duration of 5 to 10 minutes.
Ketamine (Lw Dse): Cntinuus Intravenus Infusin Related Standards & Resurces 1. Parenteral Drug Therapy Manual Mngraphs - Ketamine Skill Level: Advanced skill: Registered Nurses knwledgeable abut pharmaclgy,
More informationMEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP
MEDICATION GUIDE Piglitazne (pie-h-glit-ah-zhn) and Metfrmin (met-fore-min) Hydrchlride Tablets USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride tablets
More informationFamily Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007)
1 Family Medicine Clinical Pharmacy Frum Vl. 3, Issue 5 (September/Octber 2007) Family Medicine Clinical Pharmacy Frum is a brief bi-mnthly publicatin frm the Family Medicine clinical pharmacists distributed
More informationBP Thresholds for Medical Review
BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,
More informationRoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation
RActemra (tcilizumab) fr Giant Cell Arteritis (GCA) subcutaneus (SC) frmulatin What yu shuld knw abut RActemra This brchure prvides key infrmatin t assist in the patient s understanding f the benefits
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationSchool Medication Authorization Form. School Grade Teacher. Emergency Phone No: To be completed by the student's physician: Name of Medication:
Schl Medicatin Authrizatin Frm Student's Name Address Birth Date Hme Phne Schl Grade Teacher Emergency Phne N: T be cmpleted by the student's physician: Name f Medicatin: Dsage Frequency Time t be given
More information/0515 Medication Guide Aripiprazole Tablets
8415721/0515 Medicatin Guide Aripiprazle Tablets (air-eh-pip-rah-zle) Read this Medicatin Guide befre yu start taking aripiprazle tablets and each time yu get a refill. There may be new infrmatin. This
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationDosage Administration
Pharmacy Technician Dsage Administratin Dsage Administratin Dsage Frms and Their Usages Medicatins ften cnsist f small quantities f active ingredients cmbined with inactive ingredients t create varius
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationSAN LUIS OBISPO COUNTY HEALTH AGENCY
SAN LUIS OBISPO COUNTY HEALTH AGENCY Prtcl & Drug Frmulary Revisins / Additins Nvember 15, 2013 Public Health Department Emergency Medical Services Agency 2156 Sierra Way, San Luis Obisp, CA 93401 805-788-2511
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationMEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion
MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationNew Zealand Consumer Medicine Information. Tramadol hydrochloride immediate release capsules (50 mg) and solution for injection (50 mg/ml, 100 mg/2ml)
New Zealand Cnsumer Medicine Infrmatin TRAMAL Tramadl hydrchlride immediate release capsules (50 mg) and slutin fr injectin (50 mg/ml, 100 mg/2ml) What is in this leaflet Please read this leaflet carefully
More information5.0: Rare Bleeding Disorders
5.0: Rare Bleeding Disrders 5.1: General Infrmatin Rare bleeding disrders (RBDs) include deficiencies f factrs I (Fibringen), II, V, VII, X, XI and XIII. These deficiencies can be severe r mild. Severe
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationName of procedure: Removal of submandibular salivary gland
Oral facial surgery Surgical prcedure infrmatin leaflet Name f prcedure: Remval f submandibular salivary gland This leaflet explains sme f the benefits, risks and alternatives t the peratin. We want yu
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationMeeting Minutes. III. New Business (Slide Presentation is embedded for reference) [slides 3-47] May 2011 DMRAB Presentation PUBLIC C
Cmmnwealth f Kentucky Cabinet fr Health and Family Services Department fr Medicaid Services Drug Management Review Advisry Bard Meeting May 12, 2011 Meeting Minutes Vting Members in attendance: Kim Crley,
More information454-8 (Insert) MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place
MEDICATION GUIDE ZUBSOLV (Zub-slve) (buprenrphine and nalxne) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place away frm children. Accidental use by a child is a medical emergency and
More informationMeaningful Use Roadmap Stage Edition Eligible Hospitals
Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing
More informationAdvantage EAP Employee Assistance Program
Advantage EAP Emplyee Assistance Prgram July 2014 In This Issue What might we face? Symptms f SAD Seasnal changes in biplar disrder Tips fr cmbating summer truble When t seek help Tips fr helping thse
More informationSHARED CARE GUIDELINE For
SHARED CARE GUIDELINE Fr Lithium therapy Implementatin Date: 21.6.2011 Review Date: 21.3.2013 This guidance has been prepared and apprved fr use within Gateshead, Suth Tyneside and Sunderland in cnsultatin
More informationDrug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)
Drug Class Review: Lng-acting muscarinic antagnists (LAMAs) fr treatment f chrnic bstructive pulmnary disease (COPD) Cmprehensive Research Plan: Pharmacepidemilgy Unit April 10 th, 2014 ODPRN Drug Class
More informationPrinted copies of this document may not be up to date, obtain the most recent version from Author Position
Printed cpies f this dcument may nt be up t date, btain the mst recent versin frm www.cats.nhs.uk Children s Acute Transprt Service Clinical Guidelines Diabetic Ketacidsis Dcument Cntrl Infrmatin Authr
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationACRIN 6666 Screening Breast US Follow-up Assessment Form
Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
(Sanfi-Aventis France), NT001 Suppliers submissin f the SRA apprved text Octber 2016 Name f the medicinal prduct Text bx PACKAGE LEAFLET: INFORMATION FOR THE USER NOTEZINE 100 mg, scred tablets Diethylcarbamazine
More informationFor our protection, we require verification that you have received this notice. Therefore, please sign below.
PATIENT INFORMATION Dear Patient: Sleep prblems are extremely cmmn. Public health and safety are threatened by the increasing prevalence f bstructive sleep apnea, which nw afflicts at least 25 millin adults
More informationSECTION 2: TREATMENT OF PSYCHOSIS. Formulary and Prescribing Guidelines
SECTION 2: TREATMENT OF PSYCHOSIS Frmulary and Prescribing Guidelines 2.1 Principles f Antipsychtic Prescribing Where pssible, chice f antipsychtic shuld be made jintly by the patient and the clinician
More informationImaging tests allow the cancer care team to check for cancer and other problems inside the body.
IMAGING TESTS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between yu
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More informationThe Mental Capacity Act 2005; a short guide for the carers and relatives of those who may need support. Ian Burgess MCA Lead 13 February 2017
The Mental Capacity Act 2005; a shrt guide fr the carers and relatives f thse wh may need supprt Ian Burgess MCA Lead 13 February 2017 Agenda Overview f the MCA The 5 Principles and the legal definitin
More informationNutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:
Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationLTCH QUALITY REPORTING PROGRAM
4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04
More informationSURGICAL NOTE. Surgical Recommendations to Optimize Femoral/Iliac Artery Cannulation
SURGICAL NOTE Surgical Recmmendatins t Optimize Femral/Iliac Artery Cannulatin Due t its size, lcatin, and ease f access, the femral artery is frequently used fr bld pressure catheter placement. Less frequently,
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationIndividual Assessments for Couples Treatment with HFCA
Individual Assessments fr Cuples Treatment with HFCA Jennifer S. Ripley, Ph.D. Many appraches t cuples therapy include an individual assessment whenever a cuple cmes fr treatment. Therapists shuld be aware
More informationUniversity College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service
University Cllege Hspital Pump schl Starting n an insulin pump Children and Yung Peple s Diabetes Service 2 If yu wuld like this dcument in anther language r frmat, r require the services f an interpreter,
More informationDiphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created
More information